English
Specials
    Upgrade

    Moneycontrol

    Budget 2023Budget 2023

    PARTNERS

    • Tata AIA Life Insurance
    • Hafele
    • Motilal Oswal
    Live: Budget 2023: IT's demands
    Budget 2023
    Budget 2023
    you are here: HomeNewsTrendsHealth

    Sun Pharma acquires 3 brands to strengthen anti-inflammatory portfolio

    Acquired from Aksigen Hospital, Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India for post-operative inflammation in patients undergoing minor surgery and dental procedures

    Ayushman Kumar
    January 30, 2023 / 01:15 PM IST
    The FDA has given Sun Pharma 15 working days to respond to the warning letter, address violations and prevent their recurrence (Representative Image)

    The FDA has given Sun Pharma 15 working days to respond to the warning letter, address violations and prevent their recurrence (Representative Image)

     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Sun Pharma said on January 30 that it had acquired three drug brands from Mumbai-based Aksigen Hospital to strengthen its anti-inflammatory portfolio.

    Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, Sun Pharma said in a release.

    The addition of Disperzyme and Phlogam would further strengthen the company's anti-inflammatory portfolio. "This systemic enzyme therapy combination is being used to control edema and it speeds up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation,” Kirti Ganorkar, CEO-India business, Sun Pharma, said.

    According to the pharma firm, Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and get DCGI approval.